Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids
Olalekan O. Oluwole(Vanderbilt University), Tom van Meerten(University Medical Center Groningen), Jaeyeon Kim(Sidney Kimmel Cancer Center), Catherine Thiéblemont(Université Paris Cité), Marie José Kersten(Hovon), Caron A. Jacobson(Dana-Farber Cancer Institute), Monique C. Minnema(University Medical Center Utrecht), Abhinav Deol(Wayne State University), Javier Muñoz(The University of Texas MD Anderson Cancer Center), Saran Vardhanabhuti, John M. Timmerman(Sheba Medical Center), Nancy L. Bartlett(Washington University in St. Louis), Dimitrios Tzachanis(Dana-Farber Cancer Institute), Irit Avivi(Tel Aviv Sourasky Medical Center), Rhine R. Shen(Broad Institute), Julie M. Vose(University of Nebraska Medical Center), Édouard Forcade(Hôpital Cardiologique du Haut-Lévêque), André Goy(Hackensack University Medical Center), Jenny Nater(Kite (United States)), Yi Lin, Umar Farooq(Wake Forest University), Peter A. McSweeney(Mesoblast (United States)), Harry Miao(Takeda (United States)), Sophie de Guibert(Centre Hospitalier Universitaire de Rennes), Yan Zheng(First Affiliated Hospital of Xi'an Jiaotong University), Patrick J. Stiff(Loyola University Medical Center)
Cited by 26
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k